The current PE ratio of CSTL cannot be calculated, as the latest EPS of -$0.15 is negative. The most recent PE ratio recorded for Castle Biosciences was 40.38 in December 2024.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 40.38 | N/A | $26.65 | $0.66 |
2023 | N/A | N/A | $21.58 | -$2.14 |
2022 | N/A | N/A | $23.54 | -$2.58 |
2021 | N/A | N/A | $42.87 | -$1.24 |
2020 | N/A | N/A | $67.15 | -$0.54 |
2019 | 98.2 | N/A | $34.37 | $0.35 |
2018 | N/A | N/A | N/A | -$5.33 |
2017 | N/A | N/A | N/A | -$8.08 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $20.02 | -$0.15 |
Dec 2024 | 40.38 | -68.85% | $26.65 | $0.66 |
Sep 2024 | 129.64 | N/A | $28.52 | $0.22 |
Jun 2024 | N/A | N/A | $21.77 | -$0.12 |
Mar 2024 | N/A | N/A | $22.15 | -$1.14 |
Dec 2023 | N/A | N/A | $21.58 | -$2.14 |
Sep 2023 | N/A | N/A | $16.89 | -$2.85 |
Jun 2023 | N/A | N/A | $13.72 | -$3.36 |
Mar 2023 | N/A | N/A | $22.72 | -$2.72 |
Dec 2022 | N/A | N/A | $23.54 | -$2.58 |
Sep 2022 | N/A | N/A | $26.08 | -$2.05 |
Jun 2022 | N/A | N/A | $21.95 | -$1.75 |
Mar 2022 | N/A | N/A | $44.86 | -$2.04 |
Dec 2021 | N/A | N/A | $42.87 | -$1.24 |
Sep 2021 | N/A | N/A | $66.5 | -$1.24 |
Stock name | PE ratio | Market cap |
---|---|---|
OPTN OptiNose Inc | N/A | $94.58M |
OPK Opko Health Inc | N/A | $999.25M |
ORGO Organogenesis Holdings Inc | N/A | $677.26M |
CSTL Castle Biosciences Inc | N/A | $496.89M |
The current price to earnings ratio of CSTL cannot be determined, as its EPS of -$0.15 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.